| Description |
4-(Dodecylamino)phenol (p-DDAP) is an anticancer agent. 4-(Dodecylamino)phenol has anti-tumor activity and can suppress proliferation, arrest the cell cycle and induce apoptotic cell death. 4-(Dodecylamino)phenol can be used for the research of cancer, such as prostate cancer[1][2].
|
| Related Catalog |
|
| In Vitro |
4-(Dodecylamino)phenol (p-DDAP) (0-10 μM; 72 h) induces growth arrest in NB-39-nu cells[1]. p-DDAP (0.1, 0.2, 0.4, 10 μM; ) arrestes the cell cycle in the G0/G1 phase in dose-dependent manner[1]. p-DDAP (0.2 μM; 48 h) induces apoptotosis without differentiation[1]. p-DDAP (0.2, 0.4, 1 μM; 24 h, 72 h) induces apoptotic cell death through bcl-2 down-regulation and caspases activation[1]. Cell Proliferation Assay[1] Cell Line: NB-39-nu cells Concentration: 0-10 μM Incubation Time: 72 h Result: Showed potent growth inhibitory effects against NB-39-nu cells. Cell Cycle Analysis[1] Cell Line: NB-39-nu cells Concentration: 0.1, 0.2, 0.4, 10 μM Incubation Time: 24 h Result: Induced G0/G1-phase arrest in NB-39-nucells. Apoptosis Analysis[1] Cell Line: NB-39-nu cells Concentration: 0.2 μM Incubation Time: 48 h Result: Induced G0/G1-phase arrest, displayed morphological apoptotic features, including aggregation and nuclear fragmentation in NB-39-nu cells.
|
| In Vivo |
4-(Dodecylamino)phenol (p-DDAP) (10, 15, 40 mg/kg; i.v., daily, for 2 weeks or i.p., single) exhibits excellent anticancer efficacy against hormonal independent prostate cancer in vivo[2]. Animal Model: Specific pathogen-free athymic BALB/c nu/nu nude mice (6weeks of age, male)[2] Dosage: 10, 15, 40 mg/kg Administration: i.v., daily, for 2 weeks or i.p., single Result: Suppressed tumor growth in PC-3-implanted mice in vivo.
|
